Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) today reported financial results for the third quarter and year-to-date periods ending September 30, 2014, and reaffirmed full-year guidance for 2014 and 2015.
Financial Highlights
•Third Quarter net revenues of $31.5 million, an increase of 72% year-over-year, following the launch of TREXIMET® at the beginning of September
Help employers find you! Check out all the jobs and post your resume.
